Table 3.

Clinical Findings at the Time of Torque Teno Virus Assessment Posttransplantation, Stratified According to the Occurrence of Infection in the Subsequent Follow-up Period

Characteristics	Infection	No Infection	P Value
	(n = 41)	(n = 83)
Clinical data
Infection, n (%)	13 (32)	4 (5)c	<.001
Allograft rejection,a n (%)	9 (22)	16 (19)	.813
Antiviral treatment, n (%)	1 (2)	0 (0)	.331
Laboratory data
CMV load, copies/mL (IQR)	0 (0–140)	0 (0–20)	.082
Leukocytes, g/L (IQR)	6.3 (4.9–8.7)	6.6 (4.3–7.8)	.423
Neutrophils, g/L (IQR)	4.6 (3.8–7.5)	2.9 (4.5–6.0)	.326
Lymphocytes, g/L (IQR)	1.2 (0.7–1.5)	1.3 (0.8–1.8)	.229
eGFR, mL/min/m2 (IQR)b	47 (36–65)	50 (34–68)	.563
Urinary protein/creatinine ratio, mg/mg (IQR)	201 (105–395)	192 (98–350)	.642
CRP, mg/dL (IQR)	0.66 (0.27–2.81)	0.27 (0.08–0.70)	.023
Immunosuppression
Prednisolone, mg (IQR)	5 (5–10)	5 (5–11.25)	.174
Cyclosporine, n (%)	2 (5)	6 (7)	.719
Tacrolimus, n (%)	72 (87)	38 (93)	.384
Tacrolimus once per day, n (%)	11 (28)	13 (16)	.149
Tacrolimus trough level, ng/mL (IQR)	7.3 (5.8–9.7)	7.3 (5.6–8.8)	.524
Everolimus, n (%)	1 (2.4)	2 (2.4)	>.99
Belatacept, n (%)	1 (2.4)	4 (4.8)	.665
Mycophenolic acid, n (%)	40 (98)	80 (98)	>.99
Mycophenolic acid, g (IQR)	2 (1–2)	1 (1–2)	.842

Mann-Whitney U test was used for comparing continuous data and group comparisons were made using the Χ² test. Exact tests were used where applicable.

Abbreviations: CMV, cytomegalovirus; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; IQR, inter quartile range.

^aAny episode of biopsy-proven allograft rejection or antirejection therapy preceding torque teno virus assessment.

^beGFR was calculated using the Mayo equation [20].

^cFour patients had an infection at the time of torque teno virus assessment, but did not develop an infection in the subsequent follow-up period.